Date: 2014-10-22
Type of information: Collaboration agreement
Compound: MVA-BN®
Company: Bavarian Nordic (Denmark) Crucell, a J&J company (USA - NJ)
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On October 22, 2014, Bavarian Nordic announced that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to expand the collaboration announced earlier today to include evaluation of Bavarian Nordic\'s proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets.
Bavarian Nordic and Janssen will collaborate on the evaluation of MVA-BN for three additional infectious disease targets. Janssen is granted the exclusive option to collaborate on one or more of the targets, following scientific evaluation of MVA-BN-based vaccine candidates, which will be developed by Bavarian Nordic.
Financial terms:
Latest news:
